Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021

BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
September 01, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
August 16, 2021 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
August 16, 2021 07:55 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms

PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...
August 02, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
July 06, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
May 25, 2021 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
May 14, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
May 13, 2021 22:39 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Prices Public Offering of Common Stock

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
May 11, 2021 16:22 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...